475 related articles for article (PubMed ID: 17414440)
1. A metastatic melanoma with an unusual immunophenotypic profile.
Gao Z; Stanek A; Chen S
Am J Dermatopathol; 2007 Apr; 29(2):169-71. PubMed ID: 17414440
[TBL] [Abstract][Full Text] [Related]
2. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
3. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.
Zubovits J; Buzney E; Yu L; Duncan LM
Hum Pathol; 2004 Feb; 35(2):217-23. PubMed ID: 14991540
[TBL] [Abstract][Full Text] [Related]
4. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
5. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
6. Serological reagents for the immunohistochemical analysis of melanoma metastases in sentinel lymph nodes.
Jungbluth AA
Semin Diagn Pathol; 2008 May; 25(2):120-5. PubMed ID: 18697716
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic differences between uveal and cutaneous melanomas.
Iwamoto S; Burrows RC; Kalina RE; George D; Boehm M; Bothwell MA; Schmidt R
Arch Ophthalmol; 2002 Apr; 120(4):466-70. PubMed ID: 11934320
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45.
Shidham VB; Qi DY; Acker S; Kampalath B; Chang CC; George V; Komorowski R
Am J Surg Pathol; 2001 Aug; 25(8):1039-46. PubMed ID: 11474288
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
10. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
11. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
12. Comparative genomic hybridization in a case of melanoma that loses expression of S100, HMB45, Melan A and tyrosinase in metastasis.
Guo R; Wang X; Chen J; Gillies E; Fung KM; Li S; Hassell LA
Int J Clin Exp Pathol; 2014; 7(1):468-73. PubMed ID: 24427375
[TBL] [Abstract][Full Text] [Related]
13. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction.
Goydos JS; Ravikumar TS; Germino FJ; Yudd A; Bancila E
J Am Coll Surg; 1998 Aug; 187(2):182-8; discussion 188-90. PubMed ID: 9704966
[TBL] [Abstract][Full Text] [Related]
14. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma.
Curry BJ; Myers K; Hersey P
J Clin Oncol; 1998 May; 16(5):1760-9. PubMed ID: 9586889
[TBL] [Abstract][Full Text] [Related]
15. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
16. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry and sentinel node biopsy in melanoma: the use of tyrosinase and Melan-A.
Jarrett P; Thomson W; MacKie RM
Br J Dermatol; 1999 Aug; 141(2):361-2. PubMed ID: 10468824
[No Abstract] [Full Text] [Related]
18. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
[TBL] [Abstract][Full Text] [Related]
19. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma.
Hochberg M; Lotem M; Gimon Z; Shiloni E; Enk CD
Br J Dermatol; 2002 Feb; 146(2):244-9. PubMed ID: 11903234
[TBL] [Abstract][Full Text] [Related]
20. Loss of Conventional Melanocytic Markers in Malignant Melanoma and Lymph Node Metastasis; an Uncommon but Dangerous Pitfall.
Chang O; Argenyi Z
Am J Dermatopathol; 2017 Oct; 39(10):760-763. PubMed ID: 27759690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
